Tesamorelin + Ipamorelin Blend is supplied as one laboratory research vial containing Tesamorelin 6mg and Ipamorelin 2mg, for 8mg combined nominal content. The component amounts describe the listed material rather than a human dose or prepared solution concentration. The illustrated 3ml marking refers to container capacity.
This blend contains 8mg total at a 3:1 nominal mass ratio, with Tesamorelin listed first. The exact split is shown on the label so it cannot be confused with an equal-parts product. Published findings for Tesamorelin alone are not evidence of additional benefit from adding Ipamorelin.
Single-agent tesamorelin trials assessed visceral adiposity in a defined HIV population. Separate ipamorelin studies do not validate this 6mg/2mg mixture. The references below explain the specific study context. No direct study of this exact supplied blend was identified in this review. Comparisons should distinguish individual-component evidence from mixture-specific stability, interactions and biological activity; a source link is not an endorsement or batch certification.
Match the product designation, individual component identities and stated amounts against the relevant analytical report before drawing laboratory conclusions. The SRP research chart is explanatory, and the COA, chromatography, mass-spectrometry and traceability illustrations are educational examples, not test results for this vial. For laboratory research only; not for human or veterinary use, diagnosis or treatment.
Reviews
There are no reviews yet.